Xeris Biopharma Holdings XERS
NASDAQ XERS
$9.56 -0.42 (-4.21%)
At close: Sep 30, 2026 · 4:00 PM EDT

Xeris Biopharma Holdings (XERS) Short term Debt (2024 - 2026)

Updated

Xeris Biopharma Holdings (XERS) posted Short term Debt of $63.78 million for Q2 2026.

Analysis

Xeris Biopharma Holdings (XERS) Short term Debt (2024 - 2026) Analysis & Trends

At the end of FY2024, Xeris Biopharma Holdings' Short term Debt came in at $15.1 million.

  • The Q2 2026 figure stands as the lowest quarterly Short term Debt since Q1 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Xeris Biopharma Holdings 1.66 Bn 1.22 Bn 79.59 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 63.78 Mn
Mar 31, 2025 11.96 Mn
Dec 31, 2024 15.10 Mn
Sep 30, 2024 15.06 Mn
API Access

Xeris Biopharma Holdings Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=XERS&period=max&api_key=YOUR_API_KEY